Logo Logo Logo Logo Logo
  • About Us
    • About Odylia
    • Our Board
    • Our Team
  • Our Impact
    • reImagine
    • Our Mission
    • Get Involved
    • News
    • Rare Disease Day
  • Research & Services
    • Services Overview
    • Gene Therapy Pipeline
      • RPGRIP1 Gene Therapy
      • USH1C Gene Therapy
    • Brydge Solutions
    • Anc80 Resources
  • Resources
    • The Odylia Library
    • Rare Disease Resources
    • Fundraising Resources
    • Webinars and Presentations
    • Newsletter
  • Donate
  • About Us
    • About Odylia
    • Our Board
    • Our Team
  • Our Impact
    • reImagine
    • Our Mission
    • Get Involved
    • News
    • Rare Disease Day
  • Research & Services
    • Services Overview
    • Gene Therapy Pipeline
      • RPGRIP1 Gene Therapy
      • USH1C Gene Therapy
    • Brydge Solutions
    • Anc80 Resources
  • Resources
    • The Odylia Library
    • Rare Disease Resources
    • Fundraising Resources
    • Webinars and Presentations
    • Newsletter
  • Donate
Medibanx and Odylia Therapeutics Announce Partnership to Advance Patient-Partnered Drug Development Efforts for RPGRIP1-Associated Retinal Dystrophy

Atlanta, GA, October 2, 2023 — Medibanx, a patient-centric platform that powers medical research through the aggregation and analysis of longitudinal real-world patient data, is excited to announce a partnership with Odylia Therapeutics, a nonprofit biotechnology company focused on the development of treatments for people...

03 October, 2023
Odylia CEO & CSO, Ashley Winslow, discusses the Nonprofit Biotech model with Talking Biotech host Kevin Folta

Atlanta, GA -- September 9, 2023 A Non-Profit Biotech Model; Therapies for Rare Diseases - Dr. Ashley Winslow By Colabra • Full Transcript • View the Website This episode has two parts. The first part discusses how Odylia Therapeutics is addressing rare disease, using a novel non-profit model....

02 October, 2023
Odylia contributes to the Affordability Guidance effort spearheaded by the Innovative Genomics Institute

In 2021, IGI’s Public Impact Team launched a year-long Affordability Task Force (ATF) project aimed at solving one of the trickiest challenges for genomic medicines. The report was released in July 2023 and "is the conclusion of a yearlong deliberation by 30 individuals with expertise...

02 October, 2023
Odylia Therapeutics Announces Promotion of Ashley Winslow, Ph.D., to CEO

Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....

11 July, 2023
Odylia Therapeutics Announces Appointment of Khandan Baradaran, Ph.D. to Board of Directors

Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....

04 April, 2023
Odylia Therapeutics logo alongside JEM Therapeutics logo
Odylia Therapeutics Announces Partnership with JEM Therapeutics to Accelerate Drug Development Efforts for TECPR2-Related Disease

Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....

01 March, 2023
Andelyn Biosciences and Odylia Therapeutics partner to manufacture novel gene therapy for vision loss

Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....

31 January, 2023
Odylia Therapeutics Announces Appointment of Two New Members to Board of Directors

Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....

18 August, 2022
Odylia Announces Promotion of Ashley Winslow to President and Chief Scientific Officer

Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....

15 February, 2022
Odylia Therapeutics Granted Orphan Drug and Rare Pediatric Disease Designations by the FDA for OT-004, an Investigational Gene Therapy for RPGRIP1- associated Retinal Dystrophies

Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....

15 November, 2021
  • 1
  • 2
  • 3
  • 4
Services
  • Services Overview
  • Brydge Solutions

Visit Odylia's linked in page Visit Odylia's linked in page

Science
  • Research and Development
  • Our Mission
Resources
  • Resources
  • Webinars and Presentations
  • Clinical Trials
  • The Odylia Library
Latest News
  • Medibanx and Odylia Therapeutics Announce Partnership to Advance Patient-Partnered Drug Development Efforts for RPGRIP1-Associated Retinal Dystrophy
  • Odylia CEO & CSO, Ashley Winslow, discusses the Nonprofit Biotech model with Talking Biotech host Kevin Folta
  • Odylia contributes to the Affordability Guidance effort spearheaded by the Innovative Genomics Institute
Odylia Therapeutics logo

© 2022 Odylia Therapeutics | Registered 501(c)(3). EIN: 82-2120760 | Site by Hester Designs